Zepbound (tirzepatide) - Eli Lilly
Microdose Tirzepatide: New Study Reports 4.4- to 6.9-Pound Average Weight Loss by Day 59 (GlobeNewswire) - Sep 24, 2026 - "The analysis incorporated 93 eligible follow-up measurements from 60 adults documented as newly initiated on GLP-1 treatment. Results from the Sept. 2 data freeze were: (i) Days 14–35: 2.18% average body-weight loss, or 4.4 pounds, among 57 patients; median treatment exposure, 21 days; (ii) Days 36–59: 3.58% average loss, or 6.9 pounds, among 19 patients; median exposure, 48 days; (iii) Days 60–89: 6.10% average loss, or 12.2 pounds, among only eight patients; median exposure, 65.5 days. This small, selected subset warrants particular caution." 
Retrospective data • Obesity
https://www.globenewswire.com/news-release/2026/09/21/3365407/0/en/microdose-tirzepatide-new-study-reports-4-4-to-6-9-pound-average-weight-loss-by-day-59.html
 
Sep 24, 2026
 
Prev Next